InsiderSignal.AI

InsiderSignal.ai

BEAM - Beam Therapeutics Inc.

Insider Sale by Evans John M. (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Evans John M., serving as CEO at Beam Therapeutics Inc. (BEAM), sold 30,078 shares at $24.58 per share, for a total transaction value of $739,317.00. Following this transaction, Evans John M. now holds 1,150,205 shares of BEAM.

This sale represents a 3.00% decrease in Evans John M.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 5 days after the trade was made.

Beam Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Evans John M.

Evans John M.

CEO

John Evans is the Chief Executive Officer and Board Member of Beam Therapeutics, a position he has held since joining the company in 2017[[1]](https://beamtx.com/about-us/). He brings extensive experience as a company builder, dealmaker, and drug developer in the biotechnology industry[[1]](https://beamtx.com/about-us/). Prior to Beam, Evans served as Senior Vice President for Corporate Development and Portfolio Leadership at Agios Pharmaceuticals, where he held the role of IDH Portfolio Executive and provided strategic leadership for first-in-class IDH inhibitor programs including IDHIFA and TIBSOVO[[1]](https://beamtx.com/about-us/). At Agios, he also helped initiate and lead the company's landmark alliance with Celgene, which resulted in over $600 million in funding and investments across multiple cancer metabolism research collaborations, and co-led the company's expansion into rare genetic diseases[[1]](https://beamtx.com/about-us/). Earlier in his career, Evans worked at Infinity Pharmaceuticals, McKinsey & Company's Pharmaceuticals practice, and MedImmune[[1]](https://beamtx.com/about-us/). Under his leadership at Beam Therapeutics, the company achieved a significant milestone in March 2025 when it announced groundbreaking clinical trial results demonstrating that a single infusion of its gene-editing therapy corrected a genetic mutation in nine patients with alpha-1 antitrypsin deficiency (AATD), marking the first time a misspelled gene causing disease was corrected in this manner[[7]](https://time.com/collections/time100-health-2026/7362503/john-evans/). Evans holds an M.B.A. in Healthcare Management from Wharton, a Master's degree in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University[[1]](https://beamtx.com/about-us/). Beyond his role at Beam, he serves as a Venture Partner at ARCH Venture Partners and holds board positions at Verve Therapeutics[[3]](https://in.marketscreener.com/insider/JOHN-EVANS-A1DVAT/).

View full insider profile →

Trade Price

$24.58

Quantity

30,078

Total Value

$739,317.00

Shares Owned

1,150,205

Trade Date

Wednesday, April 1, 2026

8 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Beam Therapeutics Inc.

Company Overview

No company information available
View news mentioning BEAM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5421951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime